Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation.
Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation.
复制标题
DOI：
10.1001/jama.1982.03320400044032
复制
发表时间：
1982-04
期刊：
影响因子：
--
通讯作者：
F. Serota;S. Starr;C. Bryan;P. Koch;S. Plotkin;C. August
中科院分区：
文献类型：
--
作者：
F. Serota;S. Starr;C. Bryan;P. Koch;S. Plotkin;C. August
3例在骨髓移植后发生带状疱疹感染的患者用阿昔洛韦治疗。患者在开始治疗后24小时内疼痛缓解。他们的皮肤病变分别在治疗1、2和4天内停止进展，并在治疗两周内完全愈合。药代动力学研究表明，阿昔洛韦血浆浓度-时间曲线近似于双指数方程。药物半衰期分别为3.91、3.83和3.40 h。无环鸟苷无髓毒性，可能有助于骨髓移植受者终止水痘-带状疱疹病毒感染。
Three patients in whom herpes zoster infections developed following bone marrow transplantation were treated with acyclovir. The patients experienced pain relief within 24 hours of starting treatment. The progression of their skin lesions halted within 1, 2, and 4 days of therapy, respectively, and healed completely within two weeks of therapy. Pharmacokinetic studies indicated that acyclovir plasma concentration-time profiles approximated biexponential equations. The drug half-lives were 3.91, 3.83, and 3.40 hours, respectively. Acyclovir was not myelotoxic and may be helpful in aborting varicella-zoster virus infections in bone marrow transplant recipients.